We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+7.34%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$7.05B
AUM Growth
+$688M
(+11%)
Cap. Flow
+$306M
Cap. Flow
% of AUM
4.35%
Top 10 Holdings %
Top 10 Hldgs %
15.99%
Holding
1,149
New
136
Increased
453
Reduced
359
Closed
174
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$40.4M |
| 2 |
Amazon
AMZN
|
+$35M |
| 3 |
TJX Companies
TJX
|
+$34.6M |
| 4 |
Phillips 66
PSX
|
+$33.1M |
| 5 |
Mastercard
MA
|
+$32.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$31.7M |
| 2 |
Cigna
CI
|
+$27.3M |
| 3 |
Meta Platforms (Facebook)
META
|
+$21.6M |
| 4 |
JPMorgan Chase
JPM
|
+$21M |
| 5 |
Marvell Technology
MRVL
|
+$20.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.29% |
| 2 | Financials | 17.18% |
| 3 | Consumer Discretionary | 12.24% |
| 4 | Industrials | 11.66% |
| 5 | Healthcare | 10.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CSS
901
DELISTED
CSS Industries, Inc.
CSS
| $242K | ﹤0.01% |
17,038
+1,400
| +9% | +$21.2K |
|
|
ARAV
902
DELISTED
Aravive, Inc. Common Stock
ARAV
| $240K | ﹤0.01% |
+28,578
| New | +$301K |
|
903
Puma Biotechnology
PBYI
$406M
| $239K | ﹤0.01% |
+5,210
| New | +$251K |
|
904
Build-A-Bear
BBW
$423M
| $237K | ﹤0.01% |
26,135
-8,500
| -25% | -$71.1K |
|
905
Skywest
SKYW
$4.11B
| $237K | ﹤0.01% |
4,030
-25,900
| -87% | -$1.53M |
|
|
AE
906
DELISTED
Adams Resources & Energy Inc
AE
| $237K | ﹤0.01% |
5,571
+724
| +15% | +$30.9K |
|
907
Wells Fargo
WFC
$261B
| $234K | ﹤0.01% |
+4,460
| New | +$255K |
|
|
CADE
908
DELISTED
Cadence Bank
CADE
| $233K | ﹤0.01% |
7,131
-1,550
| -18% | -$52.7K |
|
|
LOXO
909
DELISTED
Loxo Oncology, Inc
LOXO
| $232K | ﹤0.01% |
+1,360
| New | +$229K |
|
|
ITCI
910
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $231K | ﹤0.01% |
10,625
-2,295
| -18% | -$48K |
|
911
Spok Holdings
SPOK
$221M
| $229K | ﹤0.01% |
+14,884
| New | +$225K |
|
|
NH
912
DELISTED
NantHealth, Inc
NH
| $228K | ﹤0.01% |
9,668
+5,339
| +123% | +$203K |
|
913
Adient
ADNT
$1.6B
| $227K | ﹤0.01% |
5,769
-10,746
| -65% | -$484K |
|
|
MACK
914
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $225K | ﹤0.01% |
53,643
+5,593
| +12% | +$23.6K |
|
915
Axsome Therapeutics
AXSM
$12.4B
| $219K | ﹤0.01% |
+63,365
| New | +$188K |
|
916
CEVA Inc
CEVA
$1.01B
| $216K | ﹤0.01% |
7,530
-31,931
| -81% | -$963K |
|
|
SYKE
917
DELISTED
SYKES Enterprises Inc
SYKE
| $216K | ﹤0.01% |
7,068
-6,398
| -48% | -$191K |
|
918
Plexus
PLXS
$6.81B
| $215K | ﹤0.01% |
+3,670
| New | +$225K |
|
919
Dawson Geophysical
DWSN
$155M
| $213K | ﹤0.01% |
34,461
+7,440
| +28% | +$49K |
|
|
UBNK
920
DELISTED
United Financial Bancorp, Inc.
UBNK
| $212K | ﹤0.01% |
+12,600
| New | +$222K |
|
921
Paychex
PAYX
$40.4B
| $210K | ﹤0.01% |
+2,850
| New | +$205K |
|
922
Union Pacific
UNP
$183B
| $210K | ﹤0.01% |
1,290
-1,290
| -50% | -$194K |
|
923
Foster
FSTR
$443M
| $204K | ﹤0.01% |
+9,951
| New | +$228K |
|
|
RNWK
924
DELISTED
RealNetworks Inc
RNWK
| $202K | ﹤0.01% |
68,720
+34,466
| +101% | +$116K |
|
|
ZAYO
925
DELISTED
Zayo Group Holdings, Inc.
ZAYO
| $201K | ﹤0.01% |
5,800
-24,380
| -81% | -$890K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q3 2018 Portfolio in Review
As of Q3 2018, Jacobs Levy Equity Management held 1,149 positions worth $7.05B, up 11% from $6.36B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Jacobs Levy Equity Management deployed $306M of net new capital in Q3 2018, opening 136 new positions and adding to 453 existing holdings. Its largest new stake was TJX Companies: 673,440 shares worth $37.7M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Eli Lilly, an estimated $31.7M trimmed.
- Jacobs Levy Equity Management's largest Q3 2018 buy was TJX Companies: 673,440 shares worth $37.7M.
- Jacobs Levy Equity Management added most to Alphabet (Google) Class C in Q3 2018, an estimated $40.4M increase.
- Jacobs Levy Equity Management's biggest Q3 2018 reduction was Eli Lilly, cutting an estimated $31.7M.
- Jacobs Levy Equity Management fully exited Dun & Bradstreet in Q3 2018, selling an estimated $17.2M.
- Jacobs Levy Equity Management's ten largest holdings make up 16% of its $7.05B portfolio in Q3 2018.
- Jacobs Levy Equity Management opened 136 new positions and closed 174 in Q3 2018.
- Jacobs Levy Equity Management's portfolio value rose 11% quarter-over-quarter to $7.05B.
Based on Jacobs Levy Equity Management's 13F filing for Q3 2018, filed 14 Nov 2018.